MCID: MSC007
MIFTS: 56

Muscle Hypertrophy

Categories: Genetic diseases, Rare diseases, Muscle diseases

Aliases & Classifications for Muscle Hypertrophy

MalaCards integrated aliases for Muscle Hypertrophy:

Name: Muscle Hypertrophy 54 71 29 13
Hypertrophy 42 69
Myostatin-Related Muscle Hypertrophy 56
Mslhp 71

Characteristics:

Orphanet epidemiological data:

56
myostatin-related muscle hypertrophy
Inheritance: Autosomal recessive; Age of onset: Infancy,Neonatal;

HPO:

32
muscle hypertrophy:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 54 614160
Orphanet 56 ORPHA275534
UMLS via Orphanet 70 C2931112
MedGen 40 CN069079
SNOMED-CT via HPO 65 258211005

Summaries for Muscle Hypertrophy

UniProtKB/Swiss-Prot : 71 Muscle hypertrophy: A condition characterized by increased muscle bulk and strength. Affected individuals are exceptionally strong.

MalaCards based summary : Muscle Hypertrophy, also known as hypertrophy, is related to myostatin-related muscle hypertrophy and adenoid hypertrophy, and has symptoms including skeletal muscle hypertrophy, cachexia and cyanosis. An important gene associated with Muscle Hypertrophy is MSTN (Myostatin), and among its related pathways/superpathways are NFAT and Cardiac Hypertrophy and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Acetylcholine and Mivacurium have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, heart and spinal cord, and related phenotypes are Decreased viability with paclitaxel and cardiovascular system

Wikipedia : 72 Muscle hypertrophy involves an increase in size of skeletal muscle through a growth in size of its... more...

Description from OMIM: 614160

Related Diseases for Muscle Hypertrophy

Diseases in the Muscle Hypertrophy family:

Myostatin-Related Muscle Hypertrophy

Diseases related to Muscle Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Related Disease Score Top Affiliating Genes
1 myostatin-related muscle hypertrophy 12.4
2 adenoid hypertrophy 12.2
3 myopathy, x-linked, with postural muscle atrophy 10.8
4 muscular dystrophy, congenital, 1b 10.7
5 myhre syndrome 10.7
6 muscular dystrophy-dystroglycanopathy , type b, 5 10.7
7 complement component 8 deficiency 10.4 IGF1 LEP
8 short bowel syndrome 10.2 FOXO1 IGF1 LEP
9 properdin deficiency 10.1 FHL1 NPPA
10 diabetic encephalopathy 10.1 EDN1 IGF1 LEP
11 periampullary adenoma 10.1 EDN1 IGF1 LEP
12 central nervous system rhabdomyosarcoma 10.0 FOXO1 MEF2A MYOD1
13 preeclampsia/eclampsia 1 9.9 AGT EDN1 LEP
14 myotonia 9.9
15 phosphoserine aminotransferase deficiency 9.8 FHL1 MYOD1
16 neuropathy 9.8
17 muscular dystrophy 9.8
18 cardiomyopathy 9.8
19 myotonia congenita 9.8
20 chylocele of tunica vaginalis 9.8 AGT EDN1 NPPA
21 craniosynostosis 7 9.8 AGT MYH7 NPPA
22 becker muscular dystrophy 9.7
23 multifocal motor neuropathy 9.7
24 pleural tuberculosis 9.7 AGT EDN1 LEP
25 chronic myelomonocytic leukemia 9.7 AGT EDN1 IGF1 LEP
26 radiculopathy 9.7
27 craniosynostosis 9.6 EDN1 MYH7 NPPA
28 eosinophilic variant of chromophobe renal cell carcinoma 9.6 FBXO32 MSTN MYOD1
29 mononeuropathy 9.5
30 muscular atrophy 9.5
31 esophagitis 9.5
32 multiple myeloma 9.5
33 entropion 9.5
34 tarsal tunnel syndrome 9.5
35 dysferlinopathy 9.5
36 hypertrophic pyloric stenosis 9.5
37 glucagonoma 9.5
38 pyloric stenosis 9.5
39 primary orthostatic tremor 9.5
40 duchenne muscular dystrophy 9.5
41 hiatus hernia 9.5
42 vertebrobasilar insufficiency 9.5
43 hypoxia 9.5
44 pulmonary hypertension 9.5
45 urethritis 9.5
46 myoclonus 9.5
47 crohn's disease 9.5
48 polyneuropathy 9.5
49 mitral valve stenosis 9.5
50 tremor 9.5

Graphical network of the top 20 diseases related to Muscle Hypertrophy:



Diseases related to Muscle Hypertrophy

Symptoms & Phenotypes for Muscle Hypertrophy

Clinical features from OMIM:

614160

Human phenotypes related to Muscle Hypertrophy:

32
id Description HPO Frequency HPO Source Accession
1 skeletal muscle hypertrophy 32 HP:0003712

UMLS symptoms related to Muscle Hypertrophy:


cachexia, cyanosis, dyspnea, edema, fever, headache, hepatosplenomegaly, icterus, seizures, signs and symptoms, signs and symptoms, digestive, syncope, vertigo, hot flushes

GenomeRNAi Phenotypes related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.02 IGF1 MTOR
2 Decreased viability with paclitaxel GR00179-A-2 9.02 IGF1 MTOR
3 Decreased viability with paclitaxel GR00179-A-3 9.02 MTOR

MGI Mouse Phenotypes related to Muscle Hypertrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.36 AGT EDN1 FHL1 FOXO1 GATA6 IGF1
2 growth/size/body region MP:0005378 10.31 LEP MEF2A MSTN MTOR MYOD1 SLC9A1
3 homeostasis/metabolism MP:0005376 10.25 GATA6 IGF1 KLF15 LEP MSTN MTOR
4 muscle MP:0005369 10.19 MYH7 MYOD1 NPPA SMAD4 AGT EDN1
5 mortality/aging MP:0010768 10.17 AGT EDN1 FOXO1 GATA6 HDAC4 IGF1
6 adipose tissue MP:0005375 10.08 AGT FOXO1 IGF1 KLF15 LEP MSTN
7 liver/biliary system MP:0005370 9.91 AGT FOXO1 GATA6 KLF15 LEP MSTN
8 normal MP:0002873 9.81 MTOR MYOC MYOD1 SMAD4 EDN1 FOXO1
9 renal/urinary system MP:0005367 9.61 AGT EDN1 IGF1 KLF15 LEP MSTN
10 skeleton MP:0005390 9.28 EDN1 FOXO1 HDAC4 IGF1 LEP MSTN

Drugs & Therapeutics for Muscle Hypertrophy

Drugs for Muscle Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
2
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
3
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
4
Eplerenone Approved Phase 4 107724-20-9 150310 443872
5
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
6
Allopurinol Approved Phase 4 315-30-0 2094
7
Metformin Approved Phase 4 657-24-9 14219 4091
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9 Cholinergic Agents Phase 4,Phase 2
10 Neuromuscular Agents Phase 4,Phase 2
11 Neurotransmitter Agents Phase 4,Phase 2
12 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
13 Antirheumatic Agents Phase 4,Phase 2,Phase 1
14 Botulinum Toxins Phase 4,Phase 2
15 Anesthetics Phase 4
16
Atracurium Phase 4 64228-79-1 47319
17 Cholinergic Antagonists Phase 4
18 Neuromuscular Blocking Agents Phase 4
19 Neuromuscular Nondepolarizing Agents Phase 4
20 diuretics Phase 4
21 Diuretics, Potassium Sparing Phase 4
22 Hormone Antagonists Phase 4,Phase 3,Phase 2
23 Hormones Phase 4,Phase 3,Phase 2
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
25 Mineralocorticoid Receptor Antagonists Phase 4
26 Mineralocorticoids Phase 4
27 Natriuretic Agents Phase 4
28 Antimetabolites Phase 4,Phase 3
29 Antioxidants Phase 4,Phase 1
30 Protective Agents Phase 4,Phase 1
31 Anti-Arrhythmia Agents Phase 4,Phase 2
32 Central Nervous System Depressants Phase 4,Phase 2
33 Hypoglycemic Agents Phase 4
34 Anesthetics, Local Phase 4
35 Sodium Channel Blockers Phase 4
36 carnitine Nutraceutical Phase 4
37
Perhexiline Approved Phase 2, Phase 3 6621-47-2 4746
38
Methyltestosterone Approved Phase 3,Phase 2 58-18-4 6010
39
Testosterone Approved, Investigational Phase 3,Phase 2 58-22-0 6013
40
Goserelin Approved Phase 3 65807-02-5 47725 5311128
41 calcium channel blockers Phase 2, Phase 3
42 Calcium, Dietary Phase 2, Phase 3
43 Vasodilator Agents Phase 2, Phase 3
44 Liver Extracts Phase 3
45 Anticholesteremic Agents Phase 3
46 Atorvastatin Calcium Phase 3 134523-03-8
47 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
48 Hypolipidemic Agents Phase 3
49 Lipid Regulating Agents Phase 3
50 Anabolic Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 101)

id Name Status NCT ID Phase Drugs
1 Identification of Carnitine-Responsive Cardiomyopathy Unknown status NCT01904396 Phase 4 Carnitine
2 Effect of Deep BLock on Intraoperative Surgical Conditions Completed NCT01631149 Phase 4 Surgical block (rocuronium; atracurium/mivacurium);Surgical block (rocuronium; atracurium/mivacurium)
3 Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy Completed NCT03186742 Phase 4 Eplerenone 50 mg Tab
4 Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction? Completed NCT00688480 Phase 4 Placebo;Allopurinol
5 Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Completed NCT01951404 Phase 4 Allopurinol;Placebo (for allopurinol)
6 MetfoRmin and Its Effects on Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease Active, not recruiting NCT02226510 Phase 4 Metformin XL;Placebo
7 Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques Terminated NCT00992108 Phase 4 lidocaine;chemodenervation
8 Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Unknown status NCT00989508 Phase 2, Phase 3 Perhexiline;Placebo marked PEXSIG
9 Effectiveness of Creatine Supplementation and Exercise on Muscle and Bone Completed NCT01057680 Phase 3
10 Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty Completed NCT01096524 Phase 3
11 Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart Completed NCT00317967 Phase 3 Atorvastatin;Placebo
12 Systemic Hormones and Muscle Protein Synthesis Recruiting NCT03054168 Phase 3 Sustanon 250;Zoladex
13 Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients Recruiting NCT03038594 Phase 2, Phase 3 Somatropin;0.09% Saline Solution
14 Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy Unknown status NCT02292472 Phase 2 Botulinum Toxin Type A
15 The Effect of Neuromuscular Electrical Stimulation (NMES) Completed NCT00765739 Phase 2
16 Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle Completed NCT00001960 Phase 2
17 Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM) Completed NCT00001965 Phase 2 Cyclosporine A
18 Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy Completed NCT01150461 Phase 2 losartan;placebo
19 A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy Completed NCT00001894 Phase 2
20 Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study Completed NCT00035386 Phase 2
21 Pirfenidone to Treat Hypertrophic Cardiomyopathy Completed NCT00011076 Phase 2 Pirfenidone
22 Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy Completed NCT00500552 Phase 2 Perhexiline/Placebo
23 Resistance Training in Elderly Completed NCT00744094 Phase 1, Phase 2
24 Study of Blood Flow in Heart Muscle Completed NCT00001631 Phase 2
25 5-Alpha Reductase and Anabolic Effects of Testosterone Completed NCT00475501 Phase 2 Testosterone Enanthate;Finasteride;Testosterone Enanthate;Finasteride
26 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
27 Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy Active, not recruiting NCT02010775 Phase 2 Normal saline
28 Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy Active, not recruiting NCT00260442 Phase 2
29 Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study Not yet recruiting NCT02810015 Phase 2 Botulinum Toxin Type A
30 Diffusion MRI in Heart Failure Not yet recruiting NCT02973633 Phase 1, Phase 2
31 Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma Terminated NCT01050491 Phase 2 sitaxentan;placebo
32 Biventricular Pacing in Hypertrophic Cardiomyopathy Unknown status NCT00504647 Phase 1
33 Effect of Glucosamine or Ibuprofen Combined With Physical Training in Patients With Knee-Osteoarthritis Unknown status NCT00833157 Phase 1 glucosamine sulphate;ibuprofen;placebo
34 The Effects of Repeated Bouts of Downhill Running and Curcumin Supplementation on Arterial Stiffness During Recovery Unknown status NCT02281981 Phase 1
35 Secondary Prevention in Type 2 Diabetes: Comparison of Two Different Resistance Exercise Training Protocols Completed NCT01218256 Phase 1
36 Hypertrophic Regression With N-Acetylcysteine in HCM Completed NCT01537926 Phase 1 N-acetylcysteine;Placebo
37 Exercise and Nutrition Interventions in Age-related Sarcopenia Recruiting NCT02912130 Phase 1
38 Nitrite in Hypertrophic Cardiomyopathy (HCM) Study Recruiting NCT03251287 Phase 1 Sodium Nitrate;Placebo
39 Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy Unknown status NCT01470950
40 Pascal Pascal Dynamic Contour Tonometer (DCT) Intraocular Pressure and Ocular Pulse Amplitude in Patients With Thyroid Related Orbitopathy: A Comparison to Goldmann Tonometer and to Muscles Characteristics on CT Scan Unknown status NCT00646295
41 The Reversal of Neuromuscular Adaptation in Human With Spinal Cord Injury II Unknown status NCT01968096
42 Assessment of Left Ventricular Torsion by Echocardiography Study Unknown status NCT00589836
43 Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy Completed NCT02551276 Salbutamol;Placebo
44 Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults Completed NCT02442479
45 Effectiveness of NMES Associated to Vascular Occlusion in Functional Performance and Muscle Hypertrophy in Athlete's Completed NCT02406339
46 The Effects of Lifting Light or Heavy Weights on Muscle Growth and Strength in Trained Young Men Completed NCT02139865
47 The Effect of Insect Protein on Performance and Hypertrophy Completed NCT03034239
48 The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes Completed NCT01508338
49 Post-exercise Recovery After Dietary Protein Ingestion in Healthy Young Men (Meat-Milk Study) Completed NCT01578590
50 Protein Nutrition for Muscle Hypertrophy in Older Adults Completed NCT02315391

Search NIH Clinical Center for Muscle Hypertrophy

Cochrane evidence based reviews: hypertrophy

Genetic Tests for Muscle Hypertrophy

Genetic tests related to Muscle Hypertrophy:

id Genetic test Affiliating Genes
1 Muscle Hypertrophy 29

Anatomical Context for Muscle Hypertrophy

MalaCards organs/tissues related to Muscle Hypertrophy:

39
Skeletal Muscle, Heart, Spinal Cord, Smooth Muscle, Bone, Prostate, Ovary

Publications for Muscle Hypertrophy

Articles related to Muscle Hypertrophy:

(show top 50) (show all 163)
id Title Authors Year
1
An Extremely Rare Condition: Unilateral and Isolated Temporalis Muscle Hypertrophy. ( 28740790 )
2017
2
IGF1 stimulates greater muscle hypertrophy in the absence of myostatin in male mice. ( 28533420 )
2017
3
Do metabolites that are produced during resistance exercise enhance muscle hypertrophy? ( 28776271 )
2017
4
Defining the STATus quo in muscle hypertrophy. Focus on "Overload-mediated skeletal muscle hypertrophy is not impaired by loss of myofiber STAT3". ( 28768642 )
2017
5
Myogenic Progenitor Cells Control Extracellular Matrix Production by Fibroblasts during Skeletal Muscle Hypertrophy. ( 27840022 )
2017
6
Can low-load blood-flow restriction training elicit muscle hypertrophy with modest inflammation and cellular stress, but minimal muscle damage? ( 28949007 )
2017
7
Reply to the Letter to the Editor on "Effects of Light-Emitting Diode Therapy on Muscle Hypertrophy, Gene Expression, Performance, Damage, and Delayed-Onset Muscle Soreness: Case-Control Study With a Pair of Identical Twins". ( 28644245 )
2017
8
Differential requirement for satellite cells during overload-induced muscle hypertrophy in growing versus mature mice. ( 28693603 )
2017
9
Effects of linear and daily undulating periodized resistance training programs on measures of muscle hypertrophy: a systematic review and meta-analysis. ( 28848690 )
2017
10
Strength Training with Repetitions to Failure does not Provide Additional Strength and Muscle Hypertrophy Gains in Young Women. ( 28713535 )
2017
11
Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins. ( 28935884 )
2017
12
Moderate Intensity Cycling Exercise after Upper Extremity Resistance Training Interferes Response to Muscle Hypertrophy but Not Strength Gains. ( 28912657 )
2017
13
Satellite Cells Contribution to Exercise Mediated Muscle Hypertrophy and Repair. ( 28042532 )
2017
14
Muscle hypertrophy and pseudohypertrophy. ( 28778933 )
2017
15
Myotonia in a Child with Muscle Hypertrophy. ( 28141569 )
2017
16
Teaching Video NeuroImages: Trapezius muscle hypertrophy in multifocal motor neuropathy. ( 28808176 )
2017
17
Muscle Hypertrophy in Pre-Diabetic Men after Sixteen Weeks of Resistance Training. ( 28663372 )
2017
18
Comparative Proteomic and Transcriptomic Analysis of Follistatin-Induced Skeletal Muscle Hypertrophy. ( 28810121 )
2017
19
Glucocorticoid Receptor ChIP-Seq Identifies PLCD1 as a KLF15 Target that Represses Airway Smooth Muscle Hypertrophy. ( 28375666 )
2017
20
Total training load may explain similar strength gains and muscle hypertrophy seen in aged rats submitted to resistance training and anabolic steroids. ( 28817355 )
2017
21
Effects of Light-Emitting Diode Therapy on Muscle Hypertrophy, Gene Expression, Performance, Damage, and Delayed-Onset Muscle Soreness: A Case-Control Study With a Pair of Identical Twins. ( 28665818 )
2017
22
Overload-mediated skeletal muscle hypertrophy is not impaired by loss of myofiber STAT3. ( 28659288 )
2017
23
lncRNA Chronos is an aging-induced inhibitor of muscle hypertrophy. ( 28855249 )
2017
24
The effects of short versus long inter-set rest intervals in resistance training on measures of muscle hypertrophy: A systematic review. ( 28641044 )
2017
25
Frequency: The Overlooked Resistance Training Variable for Inducing Muscle Hypertrophy? ( 27752983 )
2016
26
Effects of morning versus evening combined strength and endurance training on physical performance, muscle hypertrophy, and serum hormone concentrations. ( 27863207 )
2016
27
Passive Muscle Movements Combined With Blood Flow Restriction Can Induce Muscle Hypertrophy: 1709 Board #362 June 2, 9: 00 AM - 10: 30 AM. ( 27360628 )
2016
28
Training to Fatigue: The Answer for Standardization When Assessing Muscle Hypertrophy? ( 27677915 )
2016
29
Comparative Analyses between Skeletal Muscle miRNAomes from Large White and Min Pigs Revealed MicroRNAs Associated with Postnatal Muscle Hypertrophy. ( 27253583 )
2016
30
An intricate balance of muscle damage and protein synthesis: the key players in skeletal muscle hypertrophy following resistance training. ( 27976396 )
2016
31
PRENATAL MYONUCLEI PLAY A CRUCIAL ROLE FOR SKELETAL MUSCLE HYPERTROPHY IN RODENTS. ( 27927611 )
2016
32
Alpha-ketoglutarate promotes skeletal muscle hypertrophy and protein synthesis through Akt/mTOR signaling pathways. ( 27225984 )
2016
33
Housekeeping proteins: How useful are they in skeletal muscle diabetes studies and muscle hypertrophy models? ( 27060530 )
2016
34
The effects of resistance exercise on cocaine self-administration, muscle hypertrophy, and BDNF expression in the nucleus accumbens. ( 27137405 )
2016
35
Effects of Resistance Training Frequency on Measures of Muscle Hypertrophy: A Systematic Review and Meta-Analysis. ( 27102172 )
2016
36
Impact of high versus low fixed loads and non-linear training loads on muscle hypertrophy, strength and force development. ( 27350928 )
2016
37
Neurogenic muscle hypertrophy in a 12-year-old girl. ( 27449889 )
2016
38
Neurogenic muscle hypertrophy: a case report. ( 27738507 )
2016
39
Effect of previous strength training episode and retraining on facilitation of skeletal muscle hypertrophy and contractile properties after long-term detraining in rats. ( 27162768 )
2016
40
CL316,243, a I^3-adrenergic receptor agonist, induces muscle hypertrophy and increased strength. ( 27874066 )
2016
41
Transcriptional profiling of rat skeletal muscle hypertrophy under restriction of blood flow. ( 27613141 )
2016
42
Testosterone and trenbolone enanthate increase mature myostatin protein expression despite increasing skeletal muscle hypertrophy and satellite cell number in rodent muscle. ( 27246614 )
2016
43
Exercise quantity-dependent muscle hypertrophy in adult zebrafish (Danio rerio). ( 26951149 )
2016
44
Skeletal Muscle Hypertrophy with Concurrent Exercise Training: Contrary Evidence for an Interference Effect. ( 26932769 )
2016
45
Muscle hypertrophy as the presenting sign in a patient with a complete FHL1 deletion. ( 27409453 )
2016
46
Post-exercise blood flow restriction attenuates muscle hypertrophy. ( 27480315 )
2016
47
The dose-response relationship between resistance training volume and muscle hypertrophy: are there really still any doubts? ( 27805470 )
2016
48
Letter to the Editor: Can muscle hypertrophy cause entrapment neuropathy? ( 27419828 )
2016
49
Exome Sequencing Identified a Splice Site Mutation in FHL1 that Causes Uruguay Syndrome, an X-Linked Disorder With Skeletal Muscle Hypertrophy and Premature Cardiac Death. ( 26933038 )
2016
50
Changes in muscle fiber contractility and extracellular matrix production during skeletal muscle hypertrophy. ( 27979985 )
2016

Variations for Muscle Hypertrophy

ClinVar genetic disease variations for Muscle Hypertrophy:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 MSTN NM_005259.2(MSTN): c.373+5G> A single nucleotide variant Pathogenic rs397515373 GRCh37 Chromosome 2, 190926945: 190926945

Expression for Muscle Hypertrophy

Search GEO for disease gene expression data for Muscle Hypertrophy.

Pathways for Muscle Hypertrophy

Pathways related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 AGT EDN1 IGF1 MEF2A MTOR
2
Show member pathways
12.29 FOXO1 HDAC4 IGF1 LEP MTOR
3
Show member pathways
11.95 FBXO32 FOXO1 IGF1 SMAD4
4
Show member pathways
11.87 HDAC4 IGF1 MEF2A MTOR MYOD1
5 11.79 HDAC4 MEF2A MTOR SLC9A1 SMAD4
6 11.78 IGF1 MTOR SMAD4
7 11.73 EDN1 FOXO1 SMAD4
8 11.73 EDN1 IGF1 MTOR NPPA
9 11.71 IGF1 LEP MYOD1
10 11.71 FOXO1 MTOR MYOD1 SMAD4
11 11.6 FOXO1 MYOD1 SMAD4
12 11.55 AGT FOXO1 IGF1 KLF15 LEP MEF2A
13 11.51 EDN1 LEP SMAD4
14
Show member pathways
11.37 AGT EDN1 HDAC4 IGF1 MEF2A MTOR
15 11.26 FOXO1 HDAC4 MYOD1
16
Show member pathways
11.05 EDN1 IGF1 MTOR
17 10.95 FBXO32 IGF1 MSTN MTOR
18 10.89 MYH7 NPPA SMAD4

GO Terms for Muscle Hypertrophy

Cellular components related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 AGT EDN1 FBXO32 FHL1 FOXO1 HDAC4
2 transcription factor complex GO:0005667 9.26 GATA6 MEF2A MYOD1 SMAD4

Biological processes related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

(show all 45)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.96 EDN1 FOXO1 GATA6 HDAC4 IGF1 KLF15
2 regulation of gene expression GO:0010468 9.95 GATA6 IGF1 KLF15 MYOD1
3 response to hypoxia GO:0001666 9.92 EDN1 LEP NPPA SMAD4
4 negative regulation of cell growth GO:0030308 9.87 AGT FHL1 NPPA SMAD4
5 female pregnancy GO:0007565 9.86 AGT LEP NPPA
6 positive regulation of protein kinase B signaling GO:0051897 9.86 LEP MTOR MYOC
7 cellular response to hypoxia GO:0071456 9.86 EDN1 GATA6 MTOR SLC9A1
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 AGT IGF1 MTOR
9 positive regulation of transcription, DNA-templated GO:0045893 9.85 AGT FOXO1 GATA6 HDAC4 IGF1 KLF15
10 response to insulin GO:0032868 9.83 FOXO1 LEP MTOR NPPA
11 regulation of blood pressure GO:0008217 9.81 AGT EDN1 LEP NPPA
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 AGT IGF1 LEP MYOC
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 AGT EDN1 MTOR
14 muscle organ development GO:0007517 9.77 FHL1 IGF1 MEF2A MSTN MYOD1
15 cellular response to dexamethasone stimulus GO:0071549 9.75 FBXO32 FOXO1 MSTN
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 EDN1 HDAC4 IGF1 MTOR
17 cellular response to mechanical stimulus GO:0071260 9.72 AGT HDAC4 MTPN NPPA SLC9A1
18 regulation of blood vessel size GO:0050880 9.71 AGT EDN1 NPPA
19 cell growth GO:0016049 9.71 EDN1 MTOR MTPN SLC9A1
20 cell growth involved in cardiac muscle cell development GO:0061049 9.7 AGT NPPA
21 regulation of stress fiber assembly GO:0051492 9.69 MYOC SLC9A1
22 energy reserve metabolic process GO:0006112 9.69 LEP MTOR
23 positive regulation of renal sodium excretion GO:0035815 9.67 AGT EDN1
24 striated muscle cell differentiation GO:0051146 9.67 MTPN MYOD1
25 cellular sodium ion homeostasis GO:0006883 9.67 AGT SLC9A1
26 response to muscle stretch GO:0035994 9.67 EDN1 NPPA SLC9A1
27 response to denervation involved in regulation of muscle adaptation GO:0014894 9.66 FBXO32 HDAC4
28 response to transforming growth factor beta GO:0071559 9.66 EDN1 SMAD4
29 artery smooth muscle contraction GO:0014824 9.65 AGT EDN1
30 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 9.65 IGF1 SLC9A1
31 negative regulation of myoblast proliferation GO:2000818 9.64 MSTN MYOD1
32 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.64 EDN1 IGF1
33 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.63 HDAC4 SLC9A1
34 cellular response to starvation GO:0009267 9.63 FOXO1 MYOD1
35 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.63 EDN1 IGF1 MTOR
36 positive regulation of follicle-stimulating hormone secretion GO:0046881 9.62 LEP SMAD4
37 regulation of brown fat cell differentiation GO:0090335 9.61 LEP MTOR
38 myotube cell development GO:0014904 9.61 IGF1 MYOD1
39 bone mineralization involved in bone maturation GO:0035630 9.6 IGF1 LEP
40 positive regulation of luteinizing hormone secretion GO:0033686 9.58 LEP SMAD4
41 cardiac muscle hypertrophy in response to stress GO:0014898 9.35 GATA6 HDAC4 KLF15 MYH7 NPPA
42 positive regulation of cardiac muscle hypertrophy GO:0010613 9.1 AGT EDN1 IGF1 MEF2A MTPN SLC9A1
43 negative regulation of transcription from RNA polymerase II promoter GO:0000122 10.09 EDN1 FOXO1 GATA6 HDAC4 LEP MEF2A
44 positive regulation of cell proliferation GO:0008284 10.08 AGT EDN1 HDAC4 IGF1 LEP
45 negative regulation of apoptotic process GO:0043066 10.08 FOXO1 GATA6 IGF1 LEP SLC9A1

Molecular functions related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.76 GATA6 HDAC4 KLF15 SMAD4
2 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.73 GATA6 MEF2A MYOD1 SMAD4
3 chromatin binding GO:0003682 9.63 FOXO1 GATA6 HDAC4 MEF2A MYOD1 SMAD4
4 growth factor activity GO:0008083 9.62 AGT IGF1 LEP MSTN
5 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 9.58 GATA6 MEF2A MYOD1
6 RNA polymerase II transcription factor binding GO:0001085 9.54 GATA6 MEF2A SMAD4
7 sequence-specific DNA binding GO:0043565 9.5 FOXO1 GATA6 HDAC4 MEF2A MTPN MYOD1
8 peptide hormone receptor binding GO:0051428 9.48 LEP NPPA
9 hormone activity GO:0005179 9.02 AGT EDN1 IGF1 LEP NPPA
10 protein binding GO:0005515 10.21 AGT EDN1 FBXO32 FHL1 FOXO1 GATA6

Sources for Muscle Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....